Amid Broader Market Pressures, Dx M&A Deals See Downturn in First Half of 2022
COVID-19 brought significant attention and investment to the diagnostic industry. Coming out of the pandemic new pressures and challenges await. Director Craig Steger shares his views and insights on how firms must be strategic and agile in this new paradigm.
Article By Kelsy Ketchum / July 7, 2022
COVID-19 brought significant attention and investment to the diagnostic industry. Coming out of the pandemic new pressures and challenges await. Director Craig Steger shares his views and insights on how firms must be strategic and agile in this new paradigm.
News
Outcome Capital and YAFO Capital Announce Strategic Partnership to Expand Global Strategic and Financial Services to Biopharma and Healthcare Clients
The collaboration will allow the partners to globally expand financial advisory services and cross-border transactions for life sciences and biopharmaceutical client companies Boston & Shanghai – September 14, 2023. Outcome Capital, a specialized life science advisory and investment banking firm, and YAFO Capital, a Shanghai-based boutique investment banking and advisory firm, announced that the companies […]
Read MoreResources
Outcome Capital Life Sciences Pulse, August 2023
Outcome Capital Life Science Market Pulse August 2023 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2023. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Business Continuity Plan | Privacy Policy
